Drugs / taranabant
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT00109135 | Jan → Jun 2005 | — | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 2 | NCT00109148 | Jul 2004 → Jan 2005 | obesity disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00131430 | Aug 2005 → May 2007 | obesity disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 35 trials · 2 met primary | ||||||
| Phase 3 | NCT00430742 | Nov 2006 → Jan 2008 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Terminated | Met primary |
| Phase 3 | NCT00420589 | Oct 2006 → Feb 2008 | obesity disorder | Merck Sharp & Dohme LLC | Terminated | Met primary |
| Phase 3 | NCT00384605 | Oct 2006 → Jan 2008 | obesity disorder | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 3 | NCT00131404 | Sep 2005 → Feb 2007 | obesity disorder | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 3 | NCT00131391 | Jul 2005 → Feb 2008 | obesity disorder | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | taranabant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00420589 ↗ |
| Known as | MK0364 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00109148 ↗ |
| Action | Inhibit | “cannabinoid-1 receptor inverse agonist taranabant” PMID 20191360 ↗ Feb 2010 |